Cargando…
Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 includes the G252V and F486P mutations. XBB.1.5 has rapidly increased in frequency and has become the dominant virus in New England. The bivalent...
Autores principales: | Lasrado, Ninaad, Collier, Ai-ris Y., Miller, Jessica, Hachmann, Nicole P., Liu, Jinyan, Sciacca, Michaela, Wu, Cindy, Anand, Trisha, Bondzie, Esther A., Fisher, Jana L., Mazurek, Camille R., Patio, Robert C., Powers, Olivia, Rodrigues, Stefanie L., Rowe, Marjorie, Surve, Nehalee, Ty, Darren M., Korber, Bette, Barouch, Dan H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900747/ https://www.ncbi.nlm.nih.gov/pubmed/36747640 http://dx.doi.org/10.1101/2023.01.22.525079 |
Ejemplares similares
-
Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
por: Miller, Jessica, et al.
Publicado: (2023) -
Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023) -
Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022) -
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022) -
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023)